Orthofix International N.V.
08/04/15

Orthofix International Reports Second Quarter 2015 Financial Results

Second Quarter Highlights

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2015, including net sales of $101.0 million, diluted earnings per share from continuing operations of $0.21 and adjusted diluted earnings per share of $0.36.

"I am pleased with our second quarter results and the improving outlook for our business reflected in our higher guidance. While I believe this quarter demonstrates that we have put the right strategies in place and are making good progress, we need to continue to execute against our plan to drive similar or better results going forward," said President and Chief Executive Officer, Brad Mason.

Second Quarter Financial Results

The following table provides net sales and constant currency net sales growth by strategic business unit ("SBU") for the three months ended June 30, 2015 and 2014, respectively:

    Three Months Ended June 30,
            Constant

 

Reported Currency

(Unaudited, U.S. Dollars, in thousands)

2015 2014 Growth Growth
BioStim $ 40,703 $ 39,513 3 % 3 %
Biologics 15,274 13,853 10 % 10 %
Extremity Fixation 25,594 27,303 (6 )% 12 %
Spine Fixation   19,383   20,316 (5 )% (4 )%
Total net sales $ 100,954 $ 100,985 (0 )% 5 %
 

Net sales were flat at $101.0 million compared to the same prior year period; however, net sales increased by approximately 5.0% on a constant currency basis. Net sales increased in our BioStim and Biologics SBUs due primarily to continued expansion of our sales channels and improving execution of our commercial strategies. Net sales in our Extremity Fixation SBU decreased 6.3% (an increase of 11.8% on a constant currency basis) compared to the same prior year period. The increase in constant currency terms was primarily due to cash collections from customers. Net sales in our Spine Fixation SBU decreased 4.6% year-over-year; however, second quarter sales grew 19.0% sequentially over the first quarter, highlighting the success of the team and strategies that were put in place late last year.

Gross margin was 78.3% compared to 74.8% for the same prior year period. Gross profit increased $3.4 million to $79.0 million, compared to $75.6 million in the same prior year period, primarily due to the effects of foreign exchange rates and lower charges for inventory shrinkage in 2015 when compared to the same period of 2014. In the second quarter of 2014, we incurred $1.9 million of charges for inventory shrinkage as a result of physical counts of our field inventory as part of the remediation activities that followed our Original Restatement.

Total net margin (gross profit less sales and marketing expenses) was $36.1 million, or 35.8% of net sales, an increase of 7.6% from $33.6 million, or 33.2% of net sales, in the second quarter of 2014. The increase in net margin was driven by the increase in gross profit offset somewhat by the planned increase in sales management and field-based education and training personnel.

Operating expenses increased by $5.2 million to $74.1 million, compared to $68.9 million in the prior year period. The increase in operating expenses was primarily a result of an increase in general and administrative expenses as the Company invested in its infrastructure, an increase in share-based compensation, costs related to legal judgment, and an increase in professional fees and personnel costs within our finance department as part of our internal control remediation efforts. Operating income was $4.9 million for the quarter compared to $6.7 million in the second quarter of 2014.

Adjusted EBITDA from continuing operations, which excludes share-based compensation, foreign exchange impact, strategic investments, restatements and related costs, infrastructure investments, legal judgment, and gain on sale of assets, was $17.2 million or 17.1% of net sales for the quarter, compared to $16.2 million or 16.1% of net sales in the same prior year period.

Net income from continuing operations for the quarter was $4.1 million, or $0.21 per diluted share, compared to net income of $3.3 million, or $0.18 per diluted share, in the same prior year period.

Adjusted net income from continuing operations for the quarter was $6.8 million, or $0.36 per diluted share, compared to adjusted net income from continuing operations of $4.6 million, or $0.25 per diluted share, in the same prior year period.

As of June 30, 2015, cash and cash equivalents were $55.9 million compared to $71.2 million, which includes restricted cash, as of December 31, 2014. As of June 30, 2015, the Company had no outstanding indebtedness and borrowing capacity of $100 million. The Company's current credit facility expires August 30, 2015, and the Company is currently in negotiations to renew the credit facility, which it expects to have completed prior to the expiration of the current facility.

Fiscal 2015 Outlook

The fiscal year 2015 outlook below assumes constant currency exchange rates from those currently prevailing:

  Previous Quarter     Current Quarter
2015 Outlook 2015 Outlook
 
Net Sales

$385 million$390 million

$390 million$395 million1

 
Adjusted EBITDA

$55 million$58 million

$57 million$60 million2

 

1 Represents a year over year increase of 0.6% to 1.9% on a constant currency basis and a decrease of 3.1% to 1.8% on a reported basis.
2 Represents a year over year decrease of 13.0% to 8.4% on a constant currency basis and a decrease of 12.8% to 8.3% on a reported basis.

Conference Call

Orthofix will host a conference call today at 4:30 PM Eastern time to discuss the Company's financial results for the second quarter 2015. Interested parties may access the conference call by dialing (888) 510-1765 in the U.S. and (719) 325-2432 outside the U.S., and referencing the conference ID 7192399. A replay of the call will be available for two weeks by dialing (888) 203-1112 in the U.S. and (719) 457-0820 outside the U.S., and entering the conference ID 7192399. A webcast of the conference call may be accessed by going to the Company's website at www.orthofix.com, by clicking on the Investors link and then the Events and Presentations page.

About Orthofix

Orthofix International N.V. is a diversified, global medical device company focused on improving patients' lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, Texas, the Company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the Company's sales representatives, distributors and its subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as the Musculoskeletal Transplant Foundation and the Texas Scottish Rite Hospital for Children. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.

The forward-looking statements in this release do not constitute guarantees or promises of future performance. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to: an investigation by the Division of Enforcement of the Securities and Exchange Commission (the "SEC") and related securities class action litigation arising out of our prior accounting review and restatements of financial statements; our review of allegations of improper payments involving our Brazil-based subsidiary; the geographic concentration of certain of our sales and accounts receivable in countries or territories that are facing severe fiscal challenges; the expected sales of our products, including recently launched products; unanticipated expenditures; changing relationships with customers, suppliers, strategic partners and lenders; changes to and the interpretation of governmental regulations; the resolution of pending litigation matters (including our indemnification obligations with respect to certain product liability claims against our former sports medicine global business unit); our ongoing compliance obligations under a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services (and related terms of probation) and a deferred prosecution agreement with the U.S. Department of Justice; risks relating to the protection of intellectual property; changes to the reimbursement policies of third parties; the impact of competitive products; changes to the competitive environment; the acceptance of new products in the market; conditions of the orthopedic and spine industry; credit markets and the global economy (including the expiration of our current secured revolving credit agreement in August 2015); corporate development and market development activities, including acquisitions or divestitures; unexpected costs or operating unit performance related to recent acquisitions; and other risks described in our 2014 Annual Report on Form 10-K, Part I, Item 1A, "Risk Factors" as well as in other reports that we file in the future.

     
 
ORTHOFIX INTERNATIONAL N.V.
Condensed Consolidated Statements of Operations
 
Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited, U.S. Dollars, in thousands, except share and per share data) 2015   2014 2015   2014
Product sales $ 86,868 $ 88,579 $ 163,700 $ 176,879
Marketing service fees   14,086     12,406     27,016     24,120  
Net sales 100,954 100,985 190,716 200,999
Cost of sales   21,910     25,414     41,249     52,187  
Gross profit 79,044 75,571 149,467 148,812
Operating expenses
Sales and marketing 42,946 42,013 87,231 83,184
General and administrative 22,506 18,214 44,075 36,074
Research and development 6,451 6,313 12,296 12,246
Restatements and related costs   2,213     2,327     8,129     10,633  
  74,116     68,867     151,731     142,137  
Operating income (loss) 4,928 6,704 (2,264 ) 6,675
Other income and expense
Interest income (expense), net 74 (492 ) (198 ) (960 )
Other income   853     363     1,544     91  
  927     (129 )   1,346     (869 )
Income before income taxes 5,855 6,575 (918 ) 5,806
Income tax expense   (1,778 )   (3,309 )   (2,742 )   (4,488 )
Net income (loss) from continuing operations   4,077     3,266     (3,660 )   1,318  
Discontinued operations
Loss from discontinued operations (730 ) (5,829 ) (1,511 ) (6,623 )
Income tax benefit   225     1,880     364     2,114  
Net loss from discontinued operations   (505 )   (3,949 )   (1,147 )   (4,509 )
Net income (loss) $ 3,572   $ (683 ) $ (4,807 ) $ (3,191 )
Net income (loss) per common share—basic:
Net income (loss) from continuing operations $ 0.22 $ 0.18 $ (0.20 ) $ 0.07
Net loss from discontinued operations   (0.03 )   (0.22 )   (0.06 )   (0.24 )
Net income (loss) per common share—basic $ 0.19   $ (0.04 ) $ (0.26 ) $ (0.17 )
Net income (loss) per common share—diluted:
Net income (loss) from continuing operations $ 0.21 $ 0.18 $ (0.20 ) $ 0.07
Net loss from discontinued operations   (0.02 )   (0.22 )   (0.06 )   (0.24 )
Net income (loss) per common share—diluted $ 0.19   $ (0.04 ) $ (0.26 ) $ (0.17 )
Weighted average number of common shares:
Basic 18,769,415 18,445,348 18,750,804 18,322,185
Diluted 18,989,579 18,621,192 18,750,804 18,435,128
     
 
ORTHOFIX INTERNATIONAL N.V.
Condensed Consolidated Balance Sheets
 
June 30, December 31,
(U.S. Dollars, in thousands except share and per share data) 2015 2014
Assets (unaudited)
Current assets:
Cash and cash equivalents $ 55,946 $ 36,815
Restricted cash 34,424

Trade accounts receivable, less allowance for doubtful accounts of $7,153 and $7,285 at June 30, 2015 and December 31, 2014, respectively

58,356 61,358
Inventories 59,219 59,846
Deferred income taxes 36,970 37,413
Prepaid expenses and other current assets   24,723     26,552  
Total current assets 235,214 256,408
Property, plant and equipment, net 49,963 48,549
Patents and other intangible assets, net 5,626 7,152
Goodwill 53,565 53,565
Deferred income taxes 17,910 18,541
Other long-term assets   26,876     8,970  
Total assets $ 389,154   $ 393,185  
Liabilities and shareholders' equity
Current liabilities:
Trade accounts payable $ 17,230 $ 13,223
Other current liabilities   47,678     53,220  
Total current liabilities 64,908 66,443
Deferred income taxes 229
Other long-term liabilities   26,569     26,886  
Total liabilities 91,477 93,558
Contingencies
Shareholders' equity

Common shares $0.10 par value; 50,000,000 shares authorized; 18,839,335 and 18,611,495 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively

1,884 1,861
Additional paid-in capital 237,987 232,788
Retained earnings 60,553 65,360
Accumulated other comprehensive loss   (2,747 )   (382 )
Total shareholders' equity   297,677     299,627  
Total liabilities and shareholders' equity $ 389,154   $ 393,185  
 
 

ORTHOFIX INTERNATIONAL N.V.

Selected Financial Data

Net Sales by SBU

The following table provides net sales and constant currency net sales growth by SBU for the three and six months ended June 30, 2015 and 2014, respectively:

   
Three Months Ended June 30,
            Constant

 

Reported Currency

(Unaudited, U.S. Dollars, in thousands)

2015 2014

Growth

Growth
BioStim $ 40,703 $ 39,513 3 % 3 %
Biologics 15,274 13,853 10 % 10 %
Extremity Fixation 25,594 27,303 (6 )% 12 %
Spine Fixation   19,383   20,316 (5 )% (4 )%
Total net sales $ 100,954 $ 100,985 (0 )% 5 %
 
 
Six Months Ended June 30,
Constant

 

Reported Currency

(Unaudited, U.S. Dollars, in thousands)

2015 2014 Growth Growth
BioStim $ 78,403 $ 76,650 2 % 2 %
Biologics 29,235 26,863 9 % 9 %
Extremity Fixation 47,409 54,369 (13 )% 2 %
Spine Fixation   35,669   43,117 (17 )% (17 )%
Total net sales $ 190,716 $ 200,999 (5 )% (1 )%
 

Net Margin by SBU

The following table provides net margin by SBU for the three and six months ended June 30, 2015 and 2014, respectively:

       
Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited, U.S. Dollars, in thousands) 2015     2014 2015     2014
Net Margin
BioStim $ 16,787 $ 17,706 $ 30,800 $ 32,726
Biologics 7,285 6,496 13,229 12,997
Extremity Fixation 9,149 6,656 16,165 13,590
Spine Fixation 3,173 3,130 2,644 7,189
Corporate   (296 )   (430 )   (602 )   (874 )
Total net margin $ 36,098   $ 33,558   $ 62,236   $ 65,628  
 
As a % of net sales 35.8 % 33.2 % 32.6 % 32.7 %
 

Adjusted EBITDA

The following table reconciles reported net income (loss) from continuing operations to EBITDA (earnings before net interest expense, income tax provision, depreciation and amortization) and adjusted EBITDA for the three and six months ended June 30, 2015 and 2014. Please refer to the Non-GAAP Performance Measures section at the end of this press release for more information about the specified items below.

       
Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited, U.S. Dollars, in thousands) 2015     2014 2015     2014
Net income (loss) from continuing operations $ 4,077 $ 3,266 $ (3,660 ) $ 1,318
Interest (income) expense, net (74 ) 492 198 960
Income tax expense 1,778 3,309 2,742 4,488
Depreciation and amortization   5,267     5,913     10,575     11,516  
EBITDA $ 11,048   $ 12,980   $ 9,855   $ 18,282  
Share-based compensation 1,800 1,186 3,576 2,373
Foreign exchange impact (643 ) (251 ) 1,678 (320 )
Strategic investments 440 901
Restatements and related costs 2,213 2,327 8,129 10,633
Infrastructure investments 1,303 3,462
Legal judgment 1,066 1,066
Gain on sale of assets           (3,100 )    
Adjusted EBITDA $ 17,227   $ 16,242   $ 25,567   $ 30,968  
 
As a % of net sales 17.1 % 16.1 % 13.4 % 15.4 %
 

Adjusted Net Income from Continuing Operations

The following table reconciles reported net income (loss) from continuing operations to adjusted net income from continuing operations for the three and six months ended June 30, 2015 and 2014. Amounts are shown net of tax. Please refer to the Non-GAAP Performance Measures section at the end of this press release for more information about the specified items below.

       
Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited, U.S. Dollars, in thousands) 2015     2014 2015     2014
Net income (loss) from continuing operations $ 4,077 $ 3,266 $ (3,660 ) $ 1,318
Foreign exchange impact (404 ) (158 ) 1,057 (202 )
Strategic investments 277 568
Restatements and related costs 1,394 1,466 5,121 6,699
Infrastructure investments 821 2,181
Legal judgment 672 672
Gain on sale of assets           (1,953 )    
Adjusted net income from continuing operations $ 6,837   $ 4,574   $ 3,986   $ 7,815  
 

The following table reconciles reported earnings per diluted share (EPS) from continuing operations to adjusted earnings per diluted share from continuing operations for the three and six months ended June 30, 2015 and 2014. Some calculations may be impacted by rounding and are shown net of tax. Please refer to the Non-GAAP Performance Measures section at the end of this press release for more information about the specified items below.

       
Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited, per diluted share) 2015     2014 2015     2014
EPS from continuing operations $ 0.21 $ 0.18 $ (0.20 ) $ 0.07
Foreign exchange impact (0.02 ) (0.01 ) 0.06 (0.01 )
Strategic investments 0.02 0.03
Restatements and related costs 0.07 0.08 0.27 0.36
Infrastructure investments 0.04 0.11
Legal judgment 0.04 0.04
Gain on sale of assets           (0.10 )    
Adjusted EPS from continuing operations $ 0.36   $ 0.25   $ 0.21   $ 0.42  
 

Cash Flow Data

The following table reconciles net cash provided by operating activities to free cash flow for the six months ended June 30, 2015 and 2014. Please refer to the Non-GAAP Performance Measures section at the end of this press release for more information about the specified items below.

   
Six Months Ended
June 30,
(Unaudited, U.S. Dollars, in thousands) 2015     2014
Net cash provided by operating activities $ 8,954 $ 17,874
Less: capital expenditures   (13,576 )   (6,257 )
Free cash flow $ (4,622 ) $ 11,617  
 

Net Margin

The following table reconciles gross profit to net margin for the three and six months ended June 30, 2015 and 2014. Please refer to the Non-GAAP Performance Measures section at the end of this press release for more information about the specified items below.

       
Three Months Ended Six Months Ended
June 30, June 30,
(Unaudited, U.S. Dollars in thousands) 2015     2014 2015     2014
Gross profit $ 79,044 $ 75,571 $ 149,467 $ 148,812
Less: sales and marketing   (42,946 )   (42,013 )   (87,231 )   (83,184 )
Total net margin $ 36,098   $ 33,558   $ 62,236   $ 65,628  
 

Non-GAAP Performance Measures

The tables in this press release present reconciliations of net income (loss) from continuing operations and net income (loss) from continuing operations per diluted share calculated in accordance with U.S. GAAP to non-GAAP performance measures, referred to as "EBITDA," "Adjusted EBITDA," "Adjusted net income from continuing operations," "Adjusted earnings per diluted share," "Free cash flow" and "Net margin" that exclude the items specified in the tables. A more detailed explanation of the items excluded from these non-GAAP measures, as well as why management believes the non-GAAP measures are useful to them, is included in the Reconciliations of Non-GAAP Performance Measures section below. Certain calculations for prior periods which have been previously presented have been conformed to our current calculation methodology.

Reconciliations of Non-GAAP Performance Measures

Reconciling Items for Adjusted EBITDA, Adjusted Net Income from Continuing Operations and Adjusted Earnings Per Diluted Share from Continuing Operations

Free cash flow

Free cash flow is a non-GAAP financial measure, which is calculated by subtracting capital expenditures from cash flow from operating activities. Free cash flow is an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

Net Margin

Net margin is a non-GAAP financial measure, which is calculated by subtracting sales and marketing from gross profit. Net margin is the primary metric used by the Company's Chief Operating Decision Maker in managing the Company.

Management use of, and economic substance behind, Non-GAAP Performance Measures

Management uses non-GAAP measures to evaluate performance period-over-period, to analyze the underlying trends in the Company's business, to assess its performance relative to its competitors and to establish operational goals and forecasts that are used in allocating resources. Management uses these non-GAAP measures as the basis for assessing the ability of the underlying operations to generate cash. In addition, management uses these non-GAAP measures to further its understanding of the performance of the Company's business units. The items excluded from Orthofix's non-GAAP measures are also excluded from the profit or loss reported by the Company's business units for the purpose of analyzing their performance.

Material Limitations Associated with the Use of Non-GAAP Measures

The non-GAAP measures used in this press release may have limitations as analytical tools, and should not be considered in isolation or as a replacement for U.S. GAAP performance measures. Some of the limitations associated with the use of these non-GAAP performance measures are that they exclude items that reflect an economic cost to the Company and can have a material effect on cash flows. Similarly, equity compensation expense does not directly impact cash flows, but is part of total compensation costs accounted for under U.S. GAAP.

Compensation for Limitations Associated with Use of Non-GAAP Measures

Orthofix compensates for the limitations of its non-GAAP performance measures by relying upon its U.S. GAAP results to gain a complete picture of the Company's performance. The U.S. GAAP results provide the ability to understand the Company's performance based on a defined set of criteria. The non-GAAP measures reflect the underlying operating results of the Company's businesses, excluding non-cash items, which management believes is an important measure of the Company's overall performance. The Company provides a detailed reconciliation of the non-GAAP performance measures to their most directly comparable U.S. GAAP measures, and encourages investors to review this reconciliation.

Usefulness of Non-GAAP Measures to Investors

Orthofix believes that providing non-GAAP measures that exclude certain items provides investors with greater transparency to the information used by the Company's senior management in its financial and operational decision-making. Management believes it is important to provide investors with the same non-GAAP metrics it uses to supplement information regarding the performance and underlying trends of Orthofix's business operations in order to facilitate comparisons to its historical operating results and internally evaluate the effectiveness of the Company's operating strategies. Disclosure of these non-GAAP performance measures also facilitates comparisons of Orthofix's underlying operating performance with other companies in its industry that also supplement their U.S. GAAP results with non-GAAP performance measures.

Orthofix International N.V.
Mark Quick, 214-937-2924
markquick@orthofix.com

Source: Orthofix International N.V.

News Provided by Acquire Media